MAPT and Alzheimer disease: Importantly, targeting the disruption seen in the endosomal pathway in LOAD through preclinical trials indicates its ability to ameliorate fundamental AD pathologies such as Aβ and tau accumulation and synaptic dysfunction [18–20].